Your bio isn't merely a bunch of words , it serves as an effective tool for conversion. StreamerSuite is your go-to platform to perform spli...

A couple rescue groups got together and bought 1,500 beagles from Ridglan Farms - a very controversial breeding and biotesting facility in Wisconsin. The fir...

Investing.com -- Charles River Laboratories International has agreed to acquire PathoQuest SAS from healthcare specialist private equity fund SHS Capital and its co-investors, according to a statement. The acquisition aims to combine PathoQuest’s proprietary Next Generation Sequencing capabilities with Charles River’s global scale. This combination is expected to accelerate the adoption of advanced, animal-free biotesting methods in the industry. The financial terms of the transaction were not disclosed in the statement. The companies did not provide details about the expected timeline for completing the deal. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 2 out of 3 global portfolios are beating their benchmark indexes, with 88% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

Different kinds of nanoparticles can be conjugated with diverse biomolecular receptors and employed

Different kinds of nanoparticles can be conjugated with diverse biomolecular receptors and employed